Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says

MT Newswires Live

06/05

Charles River Laboratories (CRL) has the potential to outperform expectations in the second half of 2026, RBC Capital Markets analysts said in a Thursday note.

Analysts said that the company's "Pathways to Purpose" strategy is positioning it to capitalize on improving biotech funding and pharma investment in research and development.

RBC said that the company sees various opportunities, including in China, New Alternative Methods, and organic market share gains from a recent competitor's bankruptcy.

"We expect strong biopharma funding to continue in 2026 which combined with healthy cash runways should manifest in accelerated preclinical R&D spending growth in 2026 and into 2027," analysts said.

RBC has an outperform rating and a $215 price target on the stock.

Price: 184.94, Change: -0.85, Percent Change: -0.46

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2641514677"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2641514677\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2641514677?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 22:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641514677","market":"sg","top_or_hot":-1,"title":"Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Charles River Laboratories (CRL) has the potential to outperform expectations in the second half of 2026, RBC Capital Markets analysts said in a Thursday note.</p><p>Analysts said that the company's \"Pathways to Purpose\" strategy is positioning it to capitalize on improving biotech funding and pharma investment in research and development.</p><p>RBC said that the company sees various opportunities, including in China, New Alternative Methods, and organic market share gains from a recent competitor's bankruptcy.</p><p>\"We expect strong biopharma funding to continue in 2026 which combined with healthy cash runways should manifest in accelerated preclinical R&amp;D spending growth in 2026 and into 2027,\" analysts said.</p><p>RBC has an outperform rating and a $215 price target on the stock.</p><p>Price: 184.94, Change: -0.85, Percent Change: -0.46</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCharles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-05 22:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Charles River Laboratories (CRL) has the potential to outperform expectations in the second half of 2026, RBC Capital Markets analysts said in a Thursday note.</p><p>Analysts said that the company's \"Pathways to Purpose\" strategy is positioning it to capitalize on improving biotech funding and pharma investment in research and development.</p><p>RBC said that the company sees various opportunities, including in China, New Alternative Methods, and organic market share gains from a recent competitor's bankruptcy.</p><p>\"We expect strong biopharma funding to continue in 2026 which combined with healthy cash runways should manifest in accelerated preclinical R&amp;D spending growth in 2026 and into 2027,\" analysts said.</p><p>RBC has an outperform rating and a $215 price target on the stock.</p><p>Price: 184.94, Change: -0.85, Percent Change: -0.46</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRL","symbol_name":"查爾斯河","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2641514677","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641514677","pubTimestamp":1780671236,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Charles River Laboratories  has the potential to outperform expectations in the second half of 2026, RBC Capital Markets analysts said in a Thursday note.Analysts said that the company's \"Pathways to Purpose\" strategy is positioning it to capitalize on improving biotech funding and pharma investment in research and development.RBC said that the company sees various opportunities, including in China, New Alternative Methods, and organic market share gains from a recent competitor's bankruptcy.\"We expect strong biopharma funding to continue in 2026 which combined with healthy cash runways should manifest in accelerated preclinical R&D spending growth in 2026 and into 2027,\" analysts said.RBC has an outperform rating and a $215 price target on the stock.Price: 184.94, Change: -0.85, Percent Change: -0.46","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"CRL":"查尔斯河"},"translate_title":"加拿大皇家银行表示，Charles River Laboratories有潜力在2026年下半年跑赢大盘","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":1.5},"content_text":"Charles River Laboratories (CRL) has the potential to outperform expectations in the second half of 2026, RBC Capital Markets analysts said in a Thursday note.Analysts said that the company's \"Pathways to Purpose\" strategy is positioning it to capitalize on improving biotech funding and pharma investment in research and development.RBC said that the company sees various opportunities, including in China, New Alternative Methods, and organic market share gains from a recent competitor's bankruptcy.\"We expect strong biopharma funding to continue in 2026 which combined with healthy cash runways should manifest in accelerated preclinical R&D spending growth in 2026 and into 2027,\" analysts said.RBC has an outperform rating and a $215 price target on the stock.Price: 184.94, Change: -0.85, Percent Change: -0.46","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}